Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman

Bushra M. Ahmed, Ibrahim S. Al-Zakwani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: To determine the incidence and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.Methods: This retrospective chart review consisted of 46 patients treated with bleomycin-containing regimes at Sultan Qaboos University Hospital in Oman between January 2007 and December 2010. Data regarding patient age, chemotherapy protocol, cumulative bleomycin dose, smoking history, renal function and concurrent use of granulocyte colony stimulating factor (GCSF) were collected from the hospital's electronic database. Analyses were performed using univariate statistical techniques.Results: Of the 46 patients, 22% (n = 10) experienced bleomycin pulmonary toxicity. There was an overall mortality of 4.3% (n = 2; N = 46), with significantly more deaths in the bleomycin pulmonary toxicity group compared to the cohort that did not have bleomycin pulmonary toxicity (20% versus 0%; p = 0.043). The bleomycin pulmonary toxicity group was significantly older compared to the cohort that did not have bleomycin pulmonary toxicity (48 versus 34 years; p = 0.017). Furthermore, adriamycin, bleomycin, vinblastine, dacarbazine, as front-line chemotherapy, was found to have a trend towards increased risk of bleomycin pulmonary toxicity (90% versus 56%; p = 0.067; power = 31%). There did not seem to be significant differences in bleomycin dose (143 versus 149 units; p = 0.727), smoking status (10% versus 14%; p = 1.000) and systolic blood pressure (133 versus 131 mmHg; p = 0.746) between the two study groups.Conclusion: This study confirms a relatively high incidence of bleomycin pulmonary toxicity in a tertiary hospital in Oman. Older patients were significantly more likely to suffer bleomycin pulmonary toxicity compared to younger patients.

Original languageEnglish
Pages (from-to)3-7
Number of pages5
JournalJournal of Oncology Pharmacy Practice
Volume19
Issue number1
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Oman
Bleomycin
Lung
Incidence
Smoking
Blood Pressure
Drug Therapy
Dacarbazine
Vinblastine
Granulocyte Colony-Stimulating Factor
Tertiary Care Centers
Doxorubicin

Keywords

  • Bleomycin
  • Oman
  • pulmonary toxicity

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman. / Ahmed, Bushra M.; Al-Zakwani, Ibrahim S.

In: Journal of Oncology Pharmacy Practice, Vol. 19, No. 1, 03.2013, p. 3-7.

Research output: Contribution to journalArticle

@article{65eabfabe2bb4c2ead3c6bf0af6713b1,
title = "Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman",
abstract = "Objectives: To determine the incidence and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.Methods: This retrospective chart review consisted of 46 patients treated with bleomycin-containing regimes at Sultan Qaboos University Hospital in Oman between January 2007 and December 2010. Data regarding patient age, chemotherapy protocol, cumulative bleomycin dose, smoking history, renal function and concurrent use of granulocyte colony stimulating factor (GCSF) were collected from the hospital's electronic database. Analyses were performed using univariate statistical techniques.Results: Of the 46 patients, 22{\%} (n = 10) experienced bleomycin pulmonary toxicity. There was an overall mortality of 4.3{\%} (n = 2; N = 46), with significantly more deaths in the bleomycin pulmonary toxicity group compared to the cohort that did not have bleomycin pulmonary toxicity (20{\%} versus 0{\%}; p = 0.043). The bleomycin pulmonary toxicity group was significantly older compared to the cohort that did not have bleomycin pulmonary toxicity (48 versus 34 years; p = 0.017). Furthermore, adriamycin, bleomycin, vinblastine, dacarbazine, as front-line chemotherapy, was found to have a trend towards increased risk of bleomycin pulmonary toxicity (90{\%} versus 56{\%}; p = 0.067; power = 31{\%}). There did not seem to be significant differences in bleomycin dose (143 versus 149 units; p = 0.727), smoking status (10{\%} versus 14{\%}; p = 1.000) and systolic blood pressure (133 versus 131 mmHg; p = 0.746) between the two study groups.Conclusion: This study confirms a relatively high incidence of bleomycin pulmonary toxicity in a tertiary hospital in Oman. Older patients were significantly more likely to suffer bleomycin pulmonary toxicity compared to younger patients.",
keywords = "Bleomycin, Oman, pulmonary toxicity",
author = "Ahmed, {Bushra M.} and Al-Zakwani, {Ibrahim S.}",
year = "2013",
month = "3",
doi = "10.1177/1078155212444649",
language = "English",
volume = "19",
pages = "3--7",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman

AU - Ahmed, Bushra M.

AU - Al-Zakwani, Ibrahim S.

PY - 2013/3

Y1 - 2013/3

N2 - Objectives: To determine the incidence and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.Methods: This retrospective chart review consisted of 46 patients treated with bleomycin-containing regimes at Sultan Qaboos University Hospital in Oman between January 2007 and December 2010. Data regarding patient age, chemotherapy protocol, cumulative bleomycin dose, smoking history, renal function and concurrent use of granulocyte colony stimulating factor (GCSF) were collected from the hospital's electronic database. Analyses were performed using univariate statistical techniques.Results: Of the 46 patients, 22% (n = 10) experienced bleomycin pulmonary toxicity. There was an overall mortality of 4.3% (n = 2; N = 46), with significantly more deaths in the bleomycin pulmonary toxicity group compared to the cohort that did not have bleomycin pulmonary toxicity (20% versus 0%; p = 0.043). The bleomycin pulmonary toxicity group was significantly older compared to the cohort that did not have bleomycin pulmonary toxicity (48 versus 34 years; p = 0.017). Furthermore, adriamycin, bleomycin, vinblastine, dacarbazine, as front-line chemotherapy, was found to have a trend towards increased risk of bleomycin pulmonary toxicity (90% versus 56%; p = 0.067; power = 31%). There did not seem to be significant differences in bleomycin dose (143 versus 149 units; p = 0.727), smoking status (10% versus 14%; p = 1.000) and systolic blood pressure (133 versus 131 mmHg; p = 0.746) between the two study groups.Conclusion: This study confirms a relatively high incidence of bleomycin pulmonary toxicity in a tertiary hospital in Oman. Older patients were significantly more likely to suffer bleomycin pulmonary toxicity compared to younger patients.

AB - Objectives: To determine the incidence and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.Methods: This retrospective chart review consisted of 46 patients treated with bleomycin-containing regimes at Sultan Qaboos University Hospital in Oman between January 2007 and December 2010. Data regarding patient age, chemotherapy protocol, cumulative bleomycin dose, smoking history, renal function and concurrent use of granulocyte colony stimulating factor (GCSF) were collected from the hospital's electronic database. Analyses were performed using univariate statistical techniques.Results: Of the 46 patients, 22% (n = 10) experienced bleomycin pulmonary toxicity. There was an overall mortality of 4.3% (n = 2; N = 46), with significantly more deaths in the bleomycin pulmonary toxicity group compared to the cohort that did not have bleomycin pulmonary toxicity (20% versus 0%; p = 0.043). The bleomycin pulmonary toxicity group was significantly older compared to the cohort that did not have bleomycin pulmonary toxicity (48 versus 34 years; p = 0.017). Furthermore, adriamycin, bleomycin, vinblastine, dacarbazine, as front-line chemotherapy, was found to have a trend towards increased risk of bleomycin pulmonary toxicity (90% versus 56%; p = 0.067; power = 31%). There did not seem to be significant differences in bleomycin dose (143 versus 149 units; p = 0.727), smoking status (10% versus 14%; p = 1.000) and systolic blood pressure (133 versus 131 mmHg; p = 0.746) between the two study groups.Conclusion: This study confirms a relatively high incidence of bleomycin pulmonary toxicity in a tertiary hospital in Oman. Older patients were significantly more likely to suffer bleomycin pulmonary toxicity compared to younger patients.

KW - Bleomycin

KW - Oman

KW - pulmonary toxicity

UR - http://www.scopus.com/inward/record.url?scp=84874493294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874493294&partnerID=8YFLogxK

U2 - 10.1177/1078155212444649

DO - 10.1177/1078155212444649

M3 - Article

C2 - 22504168

AN - SCOPUS:84874493294

VL - 19

SP - 3

EP - 7

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 1

ER -